Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Honokiol is cytotoxic to MM. The good news is that conventional oncology has gotten pretty good at putting newly diagnosed multiple myeloma (MM) patients into remission. The standard-of-care induction therapy Revlimid, Velcade and Dexamethasone (RVd) achieves at least partial response 100% of the time according to studies.
The vast majority of MM patients who contact me to ask various questions regarding their newly diagnosed blood cancer have already had one or more rounds of RVd in an effort to stabilize their disease. The big question then is how to manage multiple myeloma for the long term. How does someone make sure they live beyond the 5-7 year average survival talked about in published studies?
My experience as a long-term MM survivor and MM cancer coach is that newly diagnosed myeloma patients must look beyond conventional oncological therapies. Integrative therapies such as honokiol are shown to kill MM on it’s own as well as enhance chemotherapy regimens such as Velcade.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
Have you been diagnosed with multiple myeloma? I am a MM survivor and MM cancer coach. Please scroll down the page, post a question or comment and I will reply to you ASAP.
Research has shown a fairly limited side effect profile for honokiol and it appears to be fairly well tolerated. However, its antithrombotic effects could cause hemorrhage especially in patients with conditions that would put them at a higher risk like hemophilia or Von Willebrand disease…
Honokiol has shown pro-apoptotic effects in melanoma, sarcoma, myeloma, leukemia, bladder, lung, prostate, oral squamous cell carcinoma, in glioblastome multiforme cells  and colon cancer cell lines…
So potent is honokiol’s pro-apoptotic effects that it overcomes even notoriously drug resistant neoplasms such as multiple myeloma…”
” Here we show that HNK significantly induces cytotoxicity in human multiple myeloma (MM) cell lines and tumor cells from patients with relapsed refractory MM… Furthermore, HNK enhances MM cell cytotoxicity and apoptosis induced by bortezomib…”
Honokiol (HNK) is an active component purified from magnolia, a plant used in traditional Chinese and Japanese medicine. Here we show that HNK significantly induces cytotoxicity in human multiple myeloma (MM) cell lines and tumor cells from patients with relapsed refractory MM.
Neither coculture with bone marrow stromal cells nor cytokines (interleukin-6 and insulin-like growth factor-1) protect against HNK-induced cytotoxicity. Although activation of caspases 3, 7, 8, and 9 is triggered by HNK, the pan-caspase inhibitor z-VAD-fmk does not abrogate HNK-induced apoptosis.
Importantly, release of an executioner of caspase-independent apoptosis, apoptosis-inducing factor (AIF), from mitochondria is induced by HNK treatment. HNK induces apoptosis in the SU-DHL4 cell line, which has low levels of caspase 3 and 8 associated with resistance to both conventional and novel drugs. These results suggest that HNK induces apoptosis via both caspase-dependent and -independent pathways.
Furthermore, HNK enhances MM cell cytotoxicity and apoptosis induced by bortezomib. In addition to its direct cytotoxicity to MM cells, HNK also represses tube formation by endothelial cells, suggesting that HNK inhibits neovascurization in the bone marrow microenvironment. Taken together, our results provide the preclinical rationale for clinical protocols of HNK to improve patient outcome in MM.”
“Honokiol is a small-molecule polyphenol isolated from the genus Magnolia. It is accompanied by other related polyphenols, including magnolol, with which it shares certain biologic properties. Recently, honokiol has been found to have antiangiogenic, antiinflammatory, and antitumor properties in preclinical models, without appreciable toxicity.
These findings have increased interest in bringing honokiol to the clinic as a novel chemotherapeutic agent. In addition, mechanistic studies have tried to find the mechanism(s) of action of honokiol, for two major reasons. First, knowledge of the mechanisms of action may assist development of novel synthetic analogues. Second, mechanistic actions of honokiol may lead to rational combinations with conventional chemotherapy or radiation for enhanced response to systemic cancers. In this review, we describe the findings that honokiol has two major mechanisms of action. First, it blocks signaling in tumors with defective p53 function and activated ras by directly blocking the activation of phospholipase D by activated ras. Second, honokiol induces cyclophilin D, thus potentiating the mitochondrial permeability transition pore, and causing death in cells with wild-type p53..”